Myriad Logo
  • About Myriad
    • Events & Presentations
    • Corporate Governance
    • Myriad Milestones
    • 2022 Investor Day Presentations
  • News
    • Financial
    • Corporate
    • Product
    • Pipeline
  • Financial Reporting
    • GAAP to Non-GAAP Reconciliation
    • Latest Earnings Release
      • Earnings Presentation
    • SEC Filings
    • Quarterly & Annual Reports
    • Investor FAQs
      • Email Alerts Subscription
  • Contact Us
  • About Myriad
    • Events & Presentations
    • Corporate Governance
    • Myriad Milestones
    • 2022 Investor Day Presentations
  • News
    • Financial
    • Corporate
    • Product
    • Pipeline
  • Financial Reporting
    • GAAP to Non-GAAP Reconciliation
    • Latest Earnings Release
      • Earnings Presentation
    • SEC Filings
    • Quarterly & Annual Reports
    • Investor FAQs
      • Email Alerts Subscription
  • Contact Us

News Releases

Mar 02, 2023
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
Products
Feb 28, 2023
Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes
Financial
Feb 22, 2023
Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023
Financial
Feb 09, 2023
Myriad Genetics to Participate in Upcoming Healthcare Conferences
Financial
Jan 04, 2023
Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference
Corporate
Dec 19, 2022
Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans
Corporate
Nov 29, 2022
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment
Products
Oct 31, 2022
Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member
Corporate
Sep 28, 2022
Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds
Corporate
Jun 28, 2022
Myriad Genetics Issues Inaugural Environmental, Social and Governance Report
Corporate
Jun 09, 2022
Myriad Genetics CEO Paul Diaz to Speak at Goldman Sachs 43rd Annual Global Healthcare Conference
Corporate
May 26, 2022
Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022
Corporate
May 04, 2022
Myriad Genetics CEO Paul Diaz to Speak at Bank of America Securities 2022 Healthcare Conference
Corporate
May 03, 2022
Myriad Genetics Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offering to Portfolio of Precise™ Oncology Solutions
Pipeline
Apr 28, 2022
Myriad Genetics to Release First-Quarter 2022 Financial Results on May 5, 2022
Financial
Next page
  • Payers
    • Overview
  • Investors
    • Investor Relations
    • Events & Presentations
    • Investor Day
  • News
    • Press Releases
    • Email Alerts Subscription
    • Myriad Genetics Blog
  • Careers
    • Joining the Team
Myriad Logo

Health. Illuminated.

  • Terms of Use
  • Myriad Genetics, Inc. Privacy Policy
  • Notice of Privacy Practices
  • Language Assistance
  • Cookie Preferences
  • © 2023 Myriad Genetics, Inc.